Newer Therapies in Rheumatology

Abstract

Seven of the 11 newer medications recently or soon to be approved to treat rheumatologic diseases discussed in this article are biologic agents and reflect the current ability of science to target specific components of the immune system. The other agents are molecules that are directed against specific immune pathway targets as well. All have shown superiority to placebo and in some cases have been compared to currently accepted therapies. Safety issues are generally centered around infections due to the immune-interrupting nature of these therapies.

Keywords: Gout; Polymyalgia rheumatica; Psoriatic arthritis; Rheumatoid arthritis; Scleroderma; Spondyloarthropathy; Systemic lupus; Treatment.